How to make it work

Build the operating core in Sweden as a vertically integrated clinic and pharmacy, run the United Kingdom as a separate domestic structure, add Denmark as a pure clinic with no video marketing, and defer Germany, Norway and Switzerland.

That recommendation rests on three findings that were not obvious when this atlas started. Supply is no longer the constraint, so the shortage-era assumptions can be dropped. There is no meaningful drug margin in the regulated European markets, so the business is a service fee and always was. And the thing that separates the profitable operators from the unprofitable ones is not the business model at all, it is what share of gross profit goes into paid acquisition.

Everything below is the working. Where it contradicts an earlier page in this atlas, the contradiction is flagged rather than quietly fixed.

The 2023 and 2024 shortage narrative is over, and it can be shown rather than asserted. Of 535 open German shortage records in August 2026, exactly one is a GLP-1, and it is Victoza being deliberately withdrawn across the EEA by December 2026. The EMA lists Ozempic resolved in January 2026 and Trulicity in February 2026, and has no shortage page at all for Wegovy or Mounjaro. Norway’s statutory rationing register lists one medicine, and it is not a GLP-1.

More importantly for an entrant: there is no allocation regime, no historic-volume gate and no telehealth-specific restriction in five of the six shortlisted markets. Novo Nordisk Germany states on the record that it supplies wholesalers and both bricks-and-mortar and online pharmacies, and separately that it has no influence over which products the wholesale trade supplies to pharmacies. A new partner pharmacy with no purchase history can buy.

Two things follow. First, the cold chain is a worse problem than the market believes: the European Wegovy pen allows 48 hours below 30 degrees for distribution, not the 28 days that circulates in direct-to-consumer marketing, which belongs to the American single-dose presentation. The spoiled-delivery complaints on Zava’s UK Trustpilot are the predictable outcome, not an anomaly. Second, oral semaglutide removes the cold chain entirely and launched in Germany on 1 September 2026, first in the EU. That is the single biggest change to the operating model in this category, and it arrives before most entrants could launch.

The German retail price of Mounjaro 2.5 mg is 206,80 euros, and it is reversible. Working back through the Arzneimittelpreisverordnung gives a pharmacy purchase price of 159,58 euros and a manufacturer price of exactly 154,00 euros. So the entire German pharmacy margin pool on that pack is 14,20 euros through a wholesaler, under seven per cent of retail, and it is statutorily capped. Zava’s flat 33,99 euro service fee is more than twice the whole pharmacy margin.

This reframes the category. Both listed pharmacies, Redcare and DocMorris, sell at exactly the regulated list price with no fee at all. Every euro the direct-to-consumer brands charge above it is a fee for arranging a prescription, and the list price is public against every PZN, so any customer can check it in thirty seconds.

But that is the German pharmacy’s margin, and it is not yours. We first wrote this section as "there is no drug margin", and that was wrong in a way worth correcting rather than quietly fixing. German price binding does not reach EU mail-order pharmacies shipping in, which the CJEU settled in Deutsche Parkinson Vereinigung, C-148/15. That is precisely why Zava, DoktorABC, Apomeds and Juniper all dispense from the Netherlands. A Dutch-supplied brand buys near the 154 euro manufacturer price into a market anchored at a regulated 206,80 euro shelf price. The spread is real, it is large, and it is wider than anything available in the United Kingdom.

The catch is that the spread only survives if you price by dose band. At 90 per cent monthly retention, 38.7 per cent of all patient-months sit at maintenance dose, where the drug costs 378 euros rather than 154. Modelled at 200 subscribers, a flat 299 euro subscription loses about 35,000 euros a year and the same book priced by dose band earns about 199,000. Juniper runs a constant markup and you can verify it from its own published UK ladder, where the margin is 105.90 pounds at the lowest dose and 108.00 pounds at the highest. Its German pages say Standarddosierung and ab rather than publishing a table, because naming doses would mean naming the product and it has committed to the HWG abstention.

It also corrects something this atlas previously implied. Zava does not make money on medication margin: its filed 2024 accounts show medication revenue growing 12.18m pounds while cost of sales grew 12.42m. The real model is 19.50m pounds of consultation and platform fee revenue against 12.99m of medication revenue, which is one pound fifty of fee for every pound of medicine.

The United Kingdom is the exception worth chasing, because there is no statutory margin cap. A cohort model flips from roughly minus 97 to plus 94 pounds per starter between a 30 and a 40 per cent discount off Lilly’s list price. That undisclosed discount is the highest-value piece of diligence available anywhere in this atlas.

Structure D, the pure clinic, is the cleanest thing in this atlas. You sell a care programme, write prescriptions into the ordinary national channel, and never touch the medicine. That removes the pharmacy licence question, the cross-border dispensing question and most of the price-advertising question in one move. Yazen, Fit for Livet and VektFRI all run it. Two of those three are profitable.

Structure E is the prize where it is legal. Sweden bars a prescriber controlling a pharmacy but not a pharmacy controlling a prescriber, which is the asymmetry that makes vertical integration lawful there and unlawful in Germany and Norway. Only one operator, Ayd, has used it.

Every operator in this atlas lands at 55 to 74 per cent gross margin, whether they touch the drug or not. The business model is not the variable. The separating ratio is marketing as a share of gross profit, and the line sits around 60 per cent.

Hims runs at 53 to 58 per cent and is profitable. Fit for Livet’s entire cost base is 76 per cent of gross profit and it earned 8.8m DKK on 31 staff. Yazen’s marketing alone is somewhere between 79 and 91 per cent of gross profit, and it lost 5.7m euros at nearly SEK 330m of revenue. VektFRI runs a 43 per cent operating margin on NOK 5.65m. Scale is not what fixes this.

Two independent operators converge on 350 to 400 euros of marketing per active patient per year. Treat that as the market clearing price of a GLP-1 patient-year until you have your own number. Against a Swedish or Danish subscription of roughly 300 to 400 euros a year, that means you make nothing in year one and the entire business is retention.

Which is why the two profitable operators in this atlas are the two that never spent venture money on paid acquisition, and why the affiliate and lead-generation layer is worth taking seriously as its own business rather than as a growth channel bolted onto a clinic.

Every market bans advertising prescription-only medicines to the public, and the category has split into two positions: name the molecule and hope, or name nothing and lose the search intent. Both are weaker than they look.

On 26 March 2026 the German Federal Court of Justice held in I ZR 74/25 that advertising a whole class of prescription medicines by its indications is unlawful under section 10(1) HWG, and that naming no product and no manufacturer is beside the point. That undercuts the Juniper strategy of abstention, which this atlas had treated as the conservative option. Sweden’s regulator reached the same conclusion against Yazen, reportedly catching the term GLP-1 itself and even the phrase for modern medicines.

Denmark goes further still and in a different direction: marketing a health service in video form is unlawful anywhere except your own website, whether or not a drug is named. That closes the loophole entirely and makes Meta and YouTube creative illegal regardless of how careful the copy is.

And in the United Kingdom the Advertising Standards Authority held Zava responsible for referral codes its own customers posted in a public Facebook group. If you run an affiliate or refer-a-friend scheme, you own what your affiliates say. That is now precedent and it applies from the day you launch.

Stated explicitly, because a recommendation you cannot falsify is not worth much.

• The CJEU answers C-265/26 in favour of the operators. If the German ban on advertising remote treatment is held incompatible with the freedom to provide services, Germany reopens and the cross-border structure becomes far stronger everywhere. The German court has published its own view that the rule is justified, so this is not the way to bet, but it is the biggest single swing factor.
• The Netherlands comes off the German Länderliste. That kills the cross-border model outright and hands the market to whoever holds domestic structure. Proceedings are live at VG Köln.
• You can get a manufacturer discount materially better than 30 per cent in the UK. If so, the UK becomes the first market rather than the second, and drug margin becomes a real business rather than a rounding error.
• Retention is genuinely above 70 per cent at twelve months. Yazen claims it. If it holds across the category, the paid-acquisition model works and the bootstrapped operators are simply under-investing.
• Oral products change the funnel faster than expected. No cold chain, no needles and no fridge means the operational moat that favours incumbents largely disappears, and the category becomes a marketing business almost entirely.
• Generic semaglutide arrives sooner than the patent position suggests. It is the single biggest structural change coming, and it compresses everyone’s pricing at once.

1. Get a UK manufacturer discount quoted in writing. Nothing else changes the model as much, and you cannot learn it from outside.
2. Read the Swiss health ministry letter on online practices in full. It decides whether Switzerland is a market or not, and it costs a few thousand francs to have read properly.
3. Make the pharmacy purchase price a term-sheet condition. In Germany it is the entire margin and it is not public. Ask for it before signing, not after.
4. Start the Swedish apotekstillstånd application. It is the long pole on the recommended path and the registration that precedes it, with IVO, is free.
5. Decide the advertising position deliberately, in writing, with advice. One owner is currently running two irreconcilable readings of the same German statute in the same market. Do not copy whichever competitor you looked at last.

It is not legal advice and it is not a substitute for it. It is a map of what the published law, the decided cases and the filed accounts actually say, assembled so you can instruct a lawyer efficiently rather than pay one to discover it.

Read it with how this is built, and with the open questions, which is where the things we could not establish are kept honest.